AIQ Solutions Tackles the Complex Reality of Unequal Metastatic Cancer Treatment Responses – CancerX
CancerX shared a post on LinkedIn:
“While much of cancer tech development has focused on early-stage treatment, AIQ Solutions tackles the complex reality that metastatic lesions do not all respond to treatment equally.
This is one of the key reasons CancerX and our champions are so glad to have them in the 2025 Accelerator!
They’re addressing a critical gap in advanced cancer care with pioneering technology that quantifies treatment response for each individual lesion and organ in patients with metastatic cancer— Enabling providers to more accurately predict therapy response and precisely adjust treatment protocols to address the heterogeneity of cancer growth!
This level of personalization in metastatic cancer treatment exemplifies the cutting-edge digital innovation in oncology that CancerX is committed to advancing.
We look forward to supporting their mission to transform advanced cancer care!”
More posts featuring CancerX.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023